Literature DB >> 8246286

K-ras mutations in putative preneoplastic lesions in human colon.

T P Pretlow1, T A Brasitus, N C Fulton, C Cheyer, E L Kaplan.   

Abstract

BACKGROUND: A mutation in c-K-ras (KRAS2) has long been implicated as one of the important early events in the development of a large proportion of human colon cancers. Aberrant crypt foci, putative preneoplastic lesions identified microscopically in wholemounts of colons, have been shown to occur with high frequency in the colons of animals treated with colon carcinogens and in the grossly normal mucosas of patients with colon cancer.
PURPOSE: In this study, we asked whether the mutational activation of K-ras occurs in the aberrant crypt foci of human colon.
METHODS: Grossly normal colonic mucosas were obtained from seven patients during surgery and were provided to us by the Western Division of the Cooperative Human Tissue Network located at Case Western Reserve University. A total of 42 samples, consisting of aberrant crypt foci and similarly sized normal crypt areas, were microdissected from the grossly normal colonic mucosas. The DNA region containing codon 12 of K-ras was amplified by polymerase chain reaction and analyzed for mutations by dot-blot hybridization with specific oligonucleotide probes complementary to normal or mutant sequences.
RESULTS: Mutations in codon 12 of K-ras were found in 11 (73%) of 15 aberrant crypt foci but not in any of 27 morphologically normal crypt areas from the same patients.
CONCLUSIONS: The observed high frequency of K-ras mutations in these microscopically identifiable lesions makes mutation in K-ras the earliest identified gene-mutational event in human colon tumorigenesis, establishes that it often occurs prior to the development of polyps, and is consistent with the hypothesis that aberrant crypt foci are the earliest identified precursors of human colon cancer. IMPLICATIONS: Further analysis of aberrant crypt foci may identify yet unknown early genetic events that precede human colon cancer.

Entities:  

Mesh:

Year:  1993        PMID: 8246286     DOI: 10.1093/jnci/85.24.2004

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  38 in total

1.  Identification of dysplasia in human colonic aberrant crypt foci.

Authors:  I M Siu; T G Pretlow; S B Amini; T P Pretlow
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  Characteristics of advanced- and non advanced sporadic polypoid colorectal adenomas: correlation to KRAS mutations.

Authors:  Enkh-Amar Yadamsuren; Szilvia Nagy; Laszlo Pajor; Agnes Lacza; Barna Bogner
Journal:  Pathol Oncol Res       Date:  2012-06-23       Impact factor: 3.201

3.  Aneuploidy arises at early stages of Apc-driven intestinal tumorigenesis and pinpoints conserved chromosomal loci of allelic imbalance between mouse and human.

Authors:  Paola Alberici; Emma de Pater; Joana Cardoso; Mieke Bevelander; Lia Molenaar; Jos Jonkers; Riccardo Fodde
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 4.  K-ras mutation and pancreatic adenocarcinoma.

Authors:  C Caldas; S E Kern
Journal:  Int J Pancreatol       Date:  1995-08

Review 5.  Aberrant crypt foci in colorectal carcinogenesis. Cell and crypt dynamics.

Authors:  L Roncucci; M Pedroni; F Vaccina; P Benatti; L Marzona; A De Pol
Journal:  Cell Prolif       Date:  2000-02       Impact factor: 6.831

6.  Aberrant P-cadherin expression is an early event in hyperplastic and dysplastic transformation in the colon.

Authors:  R G Hardy; C Tselepis; J Hoyland; Y Wallis; T P Pretlow; I Talbot; D S A Sanders; G Matthews; D Morton; J A Z Jankowski
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

7.  Glycemic index, nutrient density, and promotion of aberrant crypt foci in rat colon.

Authors:  D E Corpet; G Peiffer; S Taché
Journal:  Nutr Cancer       Date:  1998       Impact factor: 2.900

Review 8.  Aberrant crypt foci as microscopic precursors of colorectal cancer.

Authors:  Lei Cheng; Mao-De Lai
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

9.  Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics.

Authors:  Vassiliki Kotoula; Elpida Charalambous; Bart Biesmans; Andigoni Malousi; Eleni Vrettou; George Fountzilas; George Karkavelas
Journal:  PLoS One       Date:  2009-11-04       Impact factor: 3.240

10.  Does Mutated K-RAS Oncogene Attenuate the Effect of Sulindac in Colon Cancer Chemoprevention?

Authors:  Photini F S Rice; Kevin G Ehrichs; Mykella S Jones; Hwudarw Chen; Chiu-Hsieh Hsu; Edward R Abril; Raymond B Nagle; David G Besselsen; Jennifer K Barton; Natalia A Ignatenko
Journal:  Cancer Prev Res (Phila)       Date:  2017-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.